Nonprescription COVID-19 Test Approved by FDA
WASHINGTON – The Food and Drug Administration issued an emergency authorization for a non-prescription, over the counter nostril test for coronavirus, the agency announced on Friday.
It’s the first over the counter molecular test they have authorized for use without a prescription.
It’s also the latest in test and collection kits authorized by the FDA to track the virus. The FDA has authorized 330 such items in its rush to expand the testing capability and access in the U.S.
The test, Cue COVID-19 Test for Home and Over The Counter, which utilizes a nasal swab, can be used by adults and children over the age of two, the agency explained in a written statement. It offers results through a mobile app in about twenty minutes, and its track record is good. The test was able to identify 96% of positive samples from people showing symptoms and 100% from people with no symptoms, the agency reported.
It received an emergency use authorization from the FDA, a designation which is allowed to expand access during a crisis. The agency says it has prioritized emergency use applications that would increase access to testing or testing capabilities, such as this one.
Data from Johns Hopkins University indicates that positive tests in the U.S. have been declining since January, with an average of about 4.2% coming back positive as of March 5th. According to materials published by the World Health Organization in May, a positive test rate of less than 5% is one possible indicator that a country has the epidemic under control. The total new number of tests in the country has increased since last summer.
Acting FDA Commissioner Janet Woodcock said that the approval of this test is part of the agency’s continued effort to provide flexibility to test developers in order to speed up the availability of tests.
“The FDA will continue to expand Americans’ access to testing to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” she said.
The company that makes the test, Cue Health, told the agency that it intends to produce more than 100,000 tests per day by summer.
In The News
RICHMOND -- The Commonwealth of Virginia is expanding eligibility to get a COVID-19 vaccine to anyone 16 or older, beginning Sunday. The expansion of eligibility comes as Virginia reaches a new milestone in its vaccination program— approximately half of all adults in the Commonwealth have received... Read More
WASHINGTON -- As the U.S. death toll reached 564,000 from COVID-19, the nation’s top disease experts said Thursday normal life will return for Americans only when enough of them get vaccinated. But with more than 70,000 new infections daily, they could not predict for Congress when... Read More
An Urban Institute survey covering the first year of the coronavirus pandemic found that despite a steep drop in employment, the share of young adults reporting food insecurity or problems paying utility and medical bills actually declined compared to previous studies. “Measures of hardship look at... Read More
Johnson & Johnson's COVID-19 vaccine will remain in limbo for a while longer after government health advisers declared Wednesday that they need more evidence to decide if a handful of unusual blood clots were linked to the shot — and if so, how big the risk... Read More
WASHINGTON (AP) — President Joe Biden's COVID-19 vaccination campaign hit a snag when federal regulators recommended a "pause" in administering Johnson & Johnson shots. But the White House portrayed the action as important validation of his measured approach throughout the rollout. Biden declared Tuesday that even... Read More
CHARLESTON, S.C. - Charleston, S.C., is known for many things. Southern charm. Restaurants. Idyllic, Sun-soaked days. Being home to one of the nation’s busiest and most successful ports. But perhaps nothing brings more visitors to the city and the surrounding Lowcountry than the annual Spoleto Festival... Read More